未知生产厂商
APB-R3 (EVO301) is a long-acting injectable IL-18BP fusion protein that neutralises IL-18 signalling, developed by Evommune for chronic inflammatory diseases including atopic dermatitis.
APB-R3 (EVO301) is a long-acting injectable IL-18BP fusion protein that neutralises IL-18 signalling, developed by Evommune for chronic inflammatory diseases including atopic dermatitis.
IL-18 binding protein (IL-18BP) fusion protein. APB-R3/EVO301 is designed to neutralize the IL-18 signalling pathway to regulate inflammation; it fuses native human IL-18BP to a serum-albumin-binding (SAFA) motif, giving smaller molecular weight, extended half-life, high binding affinity/specificity for IL-18 and lower immunogenicity potential than prior IL-18-targeting approaches such as monoclonal antibodies.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
